Clinical trials: Molecular Residual Disease
CML (Chronic Myelogenous Leukemia
IIT PH1 KDS-1001 in Patients With CML
This open label, non-randomized, prospective phase I study is designed to evaluate if the addition of natural killer cell therapy (KDS-1001) to tyrosine kinase inhibitors (TKIs) for chronic myeloid leukemia (CML) patients with…
- Trial name
- NCT04808115
- Testing
- KDS-1001
- Sponsor
- Duke University
TNBC - Triple-Negative Breast Cancer, Minimal Residual Disease
CtDNA Based MRD Testing for NAC Monitoring in TNBC
A prospective, multicenter, observational study to evaluate the correlation of Molecular Residual Disease (MRD) detection using circulating tumor DNA guided test to pathological complete response (pCR) after neoadjuvant…
- Trial name
- B-STRONGER-I (NCT06230185)
- Where
- 14 sites in United States
- Volunteers
- 422 people
- Sponsor
- Personalis Inc.
Pancreatic Cancer, Advanced Cancer
The Value of Molecular Residual Disease Monitoring Based on ctDNA in Advanced or Metastatic Pancreatic Cancer
The goal of this clinical trial is to explore the value of molecular residual disease (MRD) monitoring based on ctDNA in advanced or metastatic pancreatic cancer.
- Conditions
- Pancreatic Cancer, Advanced Cancer, Metastatic Cancer
- Trial name
- MAP-01 (NCT05802420)
- Testing
- Later-line therapy
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking Union Medical College Hospital
Sensorineural Hearing Loss
Immunity After Cochlear Implantation and Perilymph Molecular Profiles in Sensorineural Hearing Loss
Many patients receiving cochlear implant (CI) have some residual hearing prior to implantation surgery. However, approximately one third of them will lose it in next 6 months after cochlear implantation.
- Trial name
- PERILOTO (NCT05670158)
- Testing
- Blood sampling, Perilymph sampling
- Where
- France
- Volunteers
- 80 people
- Sponsor
- University Hospital, Montpellier
Deep Vein Thrombosis, Cancer
Residual Vein Thrombosis and the Optimal Duration of Low Molecular Weight Heparin in Cancer Patients With Deep Vein Thrombosis
The duration of anticoagulant treatment in cancer patients with Deep Vein Thrombosis (DVT) of the lower limbs is still uncertain.
- Trial name
- Cancer-DACUS (NCT00450645)
- Testing
- low molecular weight heparin
- Where
- Italy
- Volunteers
- 300 people
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
Colorectal Cancer (MSI-H), Molecular Residual Disease
Research on Colorectal Cancer Recurrence Monitoring and Individualized Treatment Based on MRD
This study aims to evaluate whether plasma molecular residual disease (MRD), assessed using circulating tumor DNA (ctDNA), can help optimize the duration of immunotherapy in patients with metastatic microsatellite…
- Trial name
- NCT07775950
- Testing
- Discontinue NA Treatment, Continued Immunotherapy, Observation
- Where
- China
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Sun Yat-sen University
Coronary Arterial Disease (CAD)
Health Improvements by Understanding the Determinants of Residual Risk in Coronary Artery Disease and New Targets for Prevention and Treatment
Current medical treatments, in patients with stable coronary artery disease (CAD), mainly target established risk factors and are able to reduce morbidity and mortality but still leave a substantial residual risk of coronary…
- Trial name
- HURRICANE (NCT06601153)
- Testing
- Cardiac CT
- Where
- 2 sites in Italy
- Volunteers
- 961 people
- Sponsor
- Fondazione Toscana Gabriele Monasterio
Lung Neoplasms, Neoadjuvant Therapy
MRD-Guided Postoperative Surveillance and Adaptive Treatment for Resectable Lung Cancer
This study is a prospective single-arm clinical trial targeting patients with stage IB-IIIA non-small cell lung cancer (NSCLC) who have received neoadjuvant immunotherapy.
- Conditions
- Lung Neoplasms, Neoadjuvant Therapy, Immunotherapy, Minimal Residual Disease
- Trial name
- NCT07894458
- Testing
- Adaptive therapy of de-escalation and escalation based on MRD testing and pathological response
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Peking University People's Hospital
Psoriasis Vulgaris, Psoriasis
Residual Disease MEMory in PSOriasis Skin During EnstiLAR® and Narrow-band Ultraviolet B Therapy: The MEMPSOLAR Study
Psoriasis is a non-communicable chronic immune-mediated disease. Psoriatic skin is characterized by excessive proliferation of skin cells and infiltration of immune cells. The cause of psoriasis is so far unknown.
- Conditions
- Psoriasis Vulgaris, Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- MEMPSOLAR (NCT05185258)
- Testing
- Enstilar
- Where
- Denmark
- Volunteers
- 12 people
- Sponsor
- Aarhus University Hospital
Locoregionally Advanced Head and Neck Squamous Cell Carcinoma (LA-HNSCC)
Molecular Residual Disease Interception in Locoregionally-Advanced High Risk HPV+ and HPV- HNSCC
This is a phase II, open-label study to assess the efficacy of AZD2936 in terms of molecular residual disease (MRD) clearance and treatment outcome in patients with MRD after definitive treatment for high risk locoregionally…
- Trial name
- MERIDIAN (NCT05414032)
- Testing
- AZD2936
- Where
- Canada
- Volunteers
- 102 people
- Sponsor
- University Health Network, Toronto
Mycoses
Validation of Pathologic Diagnosis of Invasive Fungal Infection by Molecular Method
1. Isolate fungal DNA(Deoxyribonucleic acid) from paraffin-fixed tissue specimens to distinguish and compare Aspergillus species to the existing optical pathological diagnosis. 2. PCR(polymerase chain reaction) validation. 3.
- Trial name
- NCT02676570
- Volunteers
- 50 people
- Sponsor
- Seoul St. Mary's Hospital